Skip To Main Content
Runxiu Zhu on Muck Rack

Runxiu Zhu

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Runxiu

Contact Runxiu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial

|
By Lei Wu, Liangliang Gu, Weihao Fan, Min Wei, Tingjun Dai, Xiaoling Li, Lianchen Xiao, Dai-Shi Tian, Ruisheng Duan, Xiaofeng Li, Yuming Xu, Huaxing Meng, Ting Chen, Feng Gao, Juan Feng, Huan Yang, Cun-Jin Zhang, Qiang Meng, Zhaoyou Meng, Feng Qiu, Hongyu Zhou, Wei Qiu, Qing Zhang, Hong liu, Zhe Wu, Zhe Wang, Weizhou Zang, Feng Xiang, Jinjin Liang, Sijun Liu, Xifang Liu, Junbin Chen, Feng LI, Dehui Huang, Feipeng Zhai, Runxiu Zhu, Bingmei Deng, Zunbo Li
| Nature Verified
Abstract Although CD20-directed B cell depletion has long been used in neuromyelitis optica spectrum disorder (NMOSD), high-quality, large-scale, randomized controlled trials remain limited. In this multicenter, randomized, double-blind phase 3 trial, we evaluated obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD20 monoclonal antibody, in patients with NMOSD.
Open in Who Shared Issue with article?
See all 1 articles